_id
69105457ccc777a4e85d5572
Ticker
CRDF
Name
Cardiff Oncology Inc
Exchange
NASDAQ
Address
11055 Flintkote Avenue, San Diego, CA, United States, 92121
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cardiffoncology.com
Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Last Close
2.475
Volume
339800
Current Price
2.39
Change
-3.434343434343433
Last Updated
2025-11-29T11:49:57.049Z
Image
data:image/webp;base64,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
Ipo Date
2004-07-27T00:00:00.000Z
Market Cap
153582080
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-0.17475000000000002
Sentiment Sources
4
Rating
4.7143
Target Price
9.9286
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
120000
Cost Of Revenue
-
Gross Profit
120000
Operating Expenses
12094000
Operating Income
-11974000
Interest Expense
-
Pretax Income
-11258000
Net Income
-11258000
Eps
-0.16833385666651715
Dividends Per Share
-
Shares Outstanding
67360564
Income Tax Expense
-
EBITDA
-10764000
Operating Margin
-9978.333333333334
Total Other Income Expense Net
716000
Cash
10135000
Short Term Investments
50456000
Receivables
254000
Inventories
-
Total Current Assets
61801000
Property Plant Equipment
1430000
Total Assets
63780000
Payables
2441000
Short Term Debt
726000
Long Term Debt
-
Total Liabilities
14990000
Equity
48790000
Depreciation
494000
Change In Working Capital
-1202000
Cash From Operations
-10834000
Capital Expenditures
18000
Cash From Investing
10160000
Cash From Financing
25000
Net Change In Cash
-649000
PE
-
PB
3.2760977659356425
ROE
-23.07440049190408
ROA
-17.651301348385072
FCF
-10852000
Fcf Percent
-90.43333333333334
Piotroski FScore
1
Health Score
30
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
120000
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
120000
Quarters > 0 > income Statement > operating Expenses
12094000
Quarters > 0 > income Statement > operating Income
-11974000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-11258000
Quarters > 0 > income Statement > net Income
-11258000
Quarters > 0 > income Statement > eps
-0.16833385666651715
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
66879000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-10764000
Quarters > 0 > income Statement > operating Margin
-9978.333333333334
Quarters > 0 > income Statement > total Other Income Expense Net
716000
Quarters > 0 > balance Sheet > cash
10135000
Quarters > 0 > balance Sheet > short Term Investments
50456000
Quarters > 0 > balance Sheet > receivables
254000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
61801000
Quarters > 0 > balance Sheet > property Plant Equipment
1430000
Quarters > 0 > balance Sheet > total Assets
63780000
Quarters > 0 > balance Sheet > payables
2441000
Quarters > 0 > balance Sheet > short Term Debt
726000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
14990000
Quarters > 0 > balance Sheet > equity
48790000
Quarters > 0 > cash Flow > net Income
-11258000
Quarters > 0 > cash Flow > depreciation
494000
Quarters > 0 > cash Flow > change In Working Capital
-1202000
Quarters > 0 > cash Flow > cash From Operations
-10834000
Quarters > 0 > cash Flow > capital Expenditures
18000
Quarters > 0 > cash Flow > cash From Investing
10160000
Quarters > 0 > cash Flow > cash From Financing
25000
Quarters > 0 > cash Flow > net Change In Cash
-649000
Quarters > 0 > ratios > PE
-0.16833385666651715
Quarters > 0 > ratios > PB
3.2760977659356425
Quarters > 0 > ratios > ROE
-23.07440049190408
Quarters > 0 > ratios > ROA
-17.651301348385072
Quarters > 0 > ratios > FCF
-10852000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-90.43333333333334
Quarters > 0 > health Score
30
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
121000
Quarters > 1 > income Statement > cost Of Revenue
11580000
Quarters > 1 > income Statement > gross Profit
-11459000
Quarters > 1 > income Statement > operating Expenses
3318000
Quarters > 1 > income Statement > operating Income
-14777000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-13943000
Quarters > 1 > income Statement > net Income
-13943000
Quarters > 1 > income Statement > eps
-0.20958722905330246
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
66526000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-14683000
Quarters > 1 > income Statement > operating Margin
-12212.396694214876
Quarters > 1 > income Statement > total Other Income Expense Net
834000
Quarters > 1 > balance Sheet > cash
10784000
Quarters > 1 > balance Sheet > short Term Investments
60173000
Quarters > 1 > balance Sheet > receivables
526000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
73696000
Quarters > 1 > balance Sheet > property Plant Equipment
1642000
Quarters > 1 > balance Sheet > total Assets
75739000
Quarters > 1 > balance Sheet > payables
6010000
Quarters > 1 > balance Sheet > short Term Debt
721000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
17133000
Quarters > 1 > balance Sheet > equity
58606000
Quarters > 1 > cash Flow > net Income
-13943000
Quarters > 1 > cash Flow > depreciation
229000
Quarters > 1 > cash Flow > change In Working Capital
4003999
Quarters > 1 > cash Flow > cash From Operations
-8327999
Quarters > 1 > cash Flow > capital Expenditures
26000
Quarters > 1 > cash Flow > cash From Investing
-4983000
Quarters > 1 > cash Flow > cash From Financing
0
Quarters > 1 > cash Flow > net Change In Cash
-13311000
Quarters > 1 > ratios > PE
-0.20958722905330246
Quarters > 1 > ratios > PB
2.712983994812818
Quarters > 1 > ratios > ROE
-23.791079411664334
Quarters > 1 > ratios > ROA
-18.409273953973514
Quarters > 1 > ratios > FCF
-8353999
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-69.04131404958677
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
109000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
109000
Quarters > 2 > income Statement > operating Expenses
14491000
Quarters > 2 > income Statement > operating Income
-14382000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-13434000
Quarters > 2 > income Statement > net Income
-13434000
Quarters > 2 > income Statement > eps
-0.2819307450157398
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
47650000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-14154000
Quarters > 2 > income Statement > operating Margin
-13194.495412844037
Quarters > 2 > income Statement > total Other Income Expense Net
948000
Quarters > 2 > balance Sheet > cash
24095000
Quarters > 2 > balance Sheet > short Term Investments
55792000
Quarters > 2 > balance Sheet > receivables
405000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
82711000
Quarters > 2 > balance Sheet > property Plant Equipment
1839000
Quarters > 2 > balance Sheet > total Assets
84807000
Quarters > 2 > balance Sheet > payables
3629000
Quarters > 2 > balance Sheet > short Term Debt
716000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
13931000
Quarters > 2 > balance Sheet > equity
70876000
Quarters > 2 > cash Flow > net Income
-13434000
Quarters > 2 > cash Flow > depreciation
228000
Quarters > 2 > cash Flow > change In Working Capital
-816000
Quarters > 2 > cash Flow > cash From Operations
-12794000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-14584000
Quarters > 2 > cash Flow > cash From Financing
3000
Quarters > 2 > cash Flow > net Change In Cash
-27375000
Quarters > 2 > ratios > PE
-0.2819307450157398
Quarters > 2 > ratios > PB
1.6067991986003725
Quarters > 2 > ratios > ROE
-18.95422992268187
Quarters > 2 > ratios > ROA
-15.840673529307722
Quarters > 2 > ratios > FCF
-12794000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-117.37614678899082
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
151000
Quarters > 3 > income Statement > cost Of Revenue
96000
Quarters > 3 > income Statement > gross Profit
151000
Quarters > 3 > income Statement > operating Expenses
12723000
Quarters > 3 > income Statement > operating Income
-12572000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-11787000
Quarters > 3 > income Statement > net Income
-11787000
Quarters > 3 > income Statement > eps
-0.24736621196222455
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
47650000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-12476000
Quarters > 3 > income Statement > operating Margin
-8325.827814569537
Quarters > 3 > income Statement > total Other Income Expense Net
785000
Quarters > 3 > balance Sheet > cash
51470000
Quarters > 3 > balance Sheet > short Term Investments
40276000
Quarters > 3 > balance Sheet > receivables
773000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
95054000
Quarters > 3 > balance Sheet > property Plant Equipment
2067000
Quarters > 3 > balance Sheet > total Assets
97190000
Quarters > 3 > balance Sheet > payables
4821000
Quarters > 3 > balance Sheet > short Term Debt
710000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
14241000
Quarters > 3 > balance Sheet > equity
82949000
Quarters > 3 > cash Flow > net Income
-11787000
Quarters > 3 > cash Flow > depreciation
96000
Quarters > 3 > cash Flow > change In Working Capital
378000
Quarters > 3 > cash Flow > cash From Operations
-10267000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
4511000
Quarters > 3 > cash Flow > cash From Financing
44188000
Quarters > 3 > cash Flow > net Change In Cash
38432000
Quarters > 3 > ratios > PE
-0.24736621196222455
Quarters > 3 > ratios > PB
1.3729339714764495
Quarters > 3 > ratios > ROE
-14.20993622587373
Quarters > 3 > ratios > ROA
-12.127790924992283
Quarters > 3 > ratios > FCF
-10267000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-67.99337748344371
Quarters > 3 > health Score
35
Valuation > metrics > PE
-0.16833385666651715
Valuation > metrics > PB
3.2760977659356425
Valuation > final Score
47.23902234064357
Valuation > verdict
9.2% Overvalued
Profitability > metrics > ROE
-23.07440049190408
Profitability > metrics > ROA
-18.216533713046715
Profitability > metrics > Net Margin
-93.81666666666666
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.30723508915761427
Risk > metrics > Interest Coverage
-24.238866396761132
Risk > final Score
-37
Risk > verdict
High
Liquidity > metrics > Current Ratio
19.514051152510262
Liquidity > metrics > Quick Ratio
19.514051152510262
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-20
Prev Risks > 1
-20
Prev Risks > 2
-13
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:21:51.307Z
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AShowing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$9.9286
Analyst Picks
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 48.74% of the total shares of Cardiff Oncology Inc
1.
BlackRock Inc(5.9172%)
since
2025/06/30
2.
Vanguard Group Inc(5.6043%)
since
2025/06/30
3.
Blair William & Co(3.7942%)
since
2025/06/30
4.
Pfizer Inc(3.625%)
since
2025/06/30
5.
Vanguard Total Stock Mkt Idx Inv(3.1254%)
since
2025/07/31
6.
LAURION CAPITAL MANAGEMENT LP(2.7016%)
since
2025/06/30
7.
Geode Capital Management, LLC(2.253%)
since
2025/06/30
8.
iShares Russell 2000 ETF(2.2462%)
since
2025/08/31
9.
Adage Capital Partners Gp LLC(2.139%)
since
2025/06/30
10.
Millennium Management LLC(1.6936%)
since
2025/06/30
11.
State Street Corp(1.6934%)
since
2025/06/30
12.
Morgan Stanley - Brokerage Accounts(1.1961%)
since
2025/06/30
13.
Northern Trust Corp(1.089%)
since
2025/06/30
14.
Vanguard Institutional Extnd Mkt Idx Tr(1.0252%)
since
2025/07/31
15.
Fidelity Small Cap Index(0.9343%)
since
2025/06/30
16.
Nuveen, LLC(0.8422%)
since
2025/06/30
17.
Susquehanna International Group, LLP(0.7953%)
since
2025/06/30
18.
Mccormack Advisors International(0.7594%)
since
2025/06/30
19.
Two Sigma Investments LLC(0.6667%)
since
2025/06/30
20.
CREF Stock R3(0.6661%)
since
2025/07/31
21.
Bank of New York Mellon Corp(0.502%)
since
2025/06/30
22.
Fidelity Extended Market Index(0.4986%)
since
2025/07/31
23.
iShares Russell 2000 Value ETF(0.4623%)
since
2025/08/31
24.
Marshall Wace Asset Management Ltd(0.449%)
since
2025/06/30
25.
Vanguard Russell 2000 ETF(0.4432%)
since
2025/07/31
26.
iShares Russell 2000 Growth ETF(0.3836%)
since
2025/08/31
27.
Two Sigma Advisers, LLC(0.3091%)
since
2025/06/30
28.
NT Quality Small Cap Value(0.301%)
since
2025/06/30
29.
Northern Small Cap Value(0.301%)
since
2025/06/30
30.
UBS Group AG(0.2968%)
since
2025/06/30
31.
Royal Bank of Canada(0.2879%)
since
2025/06/30
32.
Schwab Small Cap Index(0.2408%)
since
2025/07/31
33.
NT R2000 Index Fund - NL(0.2254%)
since
2025/06/30
34.
iShares Micro-Cap ETF(0.2103%)
since
2025/08/31
35.
State St Russell Sm Cap® Indx SL Cl I(0.1936%)
since
2025/08/31
36.
Extended Equity Market Fund K(0.1919%)
since
2025/06/30
37.
NT R2000 Index Fund - DC - NL - 3(0.1797%)
since
2025/06/30
38.
Fidelity Total Market Index(0.1731%)
since
2025/07/31
39.
SPDR® Russell 2000 US Small Cap ETF(0.1679%)
since
2025/08/31
40.
Vanguard US Momentum Factor ETF(0.1534%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.